Skip to main content

Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between baseline factors and discontinuation of bisphosphonate therapy at 12 months of follow-up based on discontinuation definition I during the period 2006–2009, cohort analyses

From: Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries

  Discontinuation definition Ia
Patient baseline characteristics AdjustedbOR (95% CI)
Sex Male vs Female 1.1 (1.0-1.2)*
Race Black vs White 1.1 (0.9-1.2)
  Asian vs White 0.9 (0.8-1.0)
  Hispanic vs White 1.1 (1.0-1.3)*
  Other vs White 1.0 (0.9-1.2)
Age 70-74 vs 65-69 1.0 (0.9-1.1)
  75-79 vs 65-69 1.0 (0.9-1.1)
  80-84 vs 65-69 1.0 (0.9-1.1)
  85plus vs 65-69 1.0 (0.9-1.1)
Region Midwest vs Northeast 0.9 (0.8-1.0)
  South vs Northeast 1.1 (1.0-1.2)*
  West vs Northeast 1.0 (0.9-1.1)
Area income 45000 30000- vs < 30000 0.9 (0.8-1.0)
60000 45000- vs < 30000 0.9 (0.8-0.9)*
75000 60000- vs < 30000 0.9 (0.8-0.9)*
  75000+ vs < 30000 0.8 (0.8-0.9)*
Charlson score 1-2 vs 0 1.0 (0.9-1.1)
  > 2 vs 0 1.1 (1.0-1.2)*
Number of physician visits 6-10 vs 0-5 1.1 (1.0-1.2)
  11-15 vs 0-5 1.1 (1.0-1.2)*
  > 15 vs 0-5 1.3 (1.1-1.4)*
Hospitalization at baseline     1.0 (1.0-1.1)
Long-term care stay at baseline     0.6 (0.5-0.7)*
Fracture at baseline     0.9 (0.8-1.0)*
Dual-energy X-ray absorptiometry at baseline     0.8 (0.8-0.9)*
Internal medicine physician visit at baseline     1.0 (0.9-1.0)
Family practice physician visit at baseline     1.0 (0.9-1.1)
Oncologist visit at baseline     0.9 (0.8-1.0)*
Rheumatologist or endocrinologist visit at baseline     0.8 (0.7-0.9)*
Osteoporosis     0.8 (0.8-0.9)*
Proton pump inhibitors     0.8 (0.7-1.0)*
  1. aDiscontinuation definition I: Totally discontinued all anti-osteoporosis drugs as of the end of follow up.
  2. bAdjusted for all factors listed in the table, and urban/rural residency, entering Medicare part D coverage gap at baseline, glucocorticoid-related and fall-related (predisposing to falls) conditions, diabetes, chronic kidney disease, depressive illness, acute myocardial infarction, other heart disease, metabolic bone disease, cancer, anticonvulsants, antidepressants, antipsychotics, antihypertensives, lipid-lowering drugs, non-steroidal anti-inflammatory drugs, steroids, H2-receptor blockers, hormone replacement therapy, thiazolidinediones, and aromatase inhibitors.
  3. *p < =0.05.